Valiant Laboratories
Valiant Laboratories Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Valiant Laboratories Limited, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
Valiant Laboratories Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Valiant Laboratories Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Valiant Laboratories Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Valiant Laboratories Limited, switchable between annual and quarterly views, consolidated or standalone.
Valiant Laboratories Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹371.5 Cr and reported EPS of ₹-0.05.
| Period | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue from Operations | 182 | 133 | 237 |
| Other Income | 10 | 5 | 2 |
| Total Income | 192 | 139 | 240 |
| Cost of Goods Sold (COGS) | 168 | 117 | 197 |
| Gross Profit | 14 | 17 | 40 |
| +Operating Expenses | 22 | 21 | 34 |
| EBITDA | -8 | -5 | 6 |
| +Non-Operating Expenses | 2 | 2 | 8 |
| Profit Before Tax (PBT) | -1 | -2 | 1 |
| +Tax Expense | -1 | 1 | 4 |
| Total Profit for Period | 0 | -2 | -3 |
| Net Profit (Owner's PAT) | 0 | -2 | -3 |
| Earnings Per Share (EPS) | 0.06 | -0.41 | -0.60 |
| Diluted Shares Outstanding (Nos.) | 5 | 5 | 5 |
| +Additional Disclosures | 361 | 257 | 436 |
| Sales Growth % | — | -26.74 | 78.04 |
| YoY Sales Growth % | — | -26.74 | 78.04 |
| Material Cost % | 93 | 84 | 80 |
| Employee Cost % | 2 | 3 | 3 |
| Other Cost % | 10 | 13 | 11 |
| OPM % | -5 | -4 | 3 |
| Tax % | 142 | -46 | 525 |
| Profit Growth % | — | -788.67 | -48.46 |
| Gross Margin % | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | -0.00 | -0.00 | 0.00 |
| Interest Coverage Ratio | -0.00 | -0.00 | 0.00 |
| +Additional Fields | -10 | -7 | 0 |
Valiant Laboratories segment analysis: revenue and profit mix.
Disclosed business segments at Valiant Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Valiant Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Valiant Laboratories Limited.
Our AI distills the core fundamental drivers supporting Valiant Laboratories Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Valiant Laboratories Limited's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter confidence remains high with 74.9% consistent shareholding.
Robust quarterly sales growth of 148% to 46.8 Cr.
Impressive 457% quarterly PAT growth signals potential operational turnaround.
Manageable debt-to-equity ratio of 0.52 indicates healthy financial structure.
Specialization in paracetamol, a globally demanded API, ensures market relevance.
What can break it.
Exceptionally high P/E ratio of 3357.61 suggests significant overvaluation.
Negative ROE (-1.43%) and ROCE (-0.95%) indicate inefficient capital utilization.
Negative operating profit margin (-1.23%) highlights operational efficiency challenges.
Significant decline in FII/DII holdings signals waning institutional investor confidence.
Negative 3-year revenue growth (-13.80%) shows declining top-line trend.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Valiant Laboratories Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Valiant Laboratories Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
Valiant Laboratories Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Valiant Laboratories Limited — derived from the live tape, not yesterday's close.
Valiant Laboratories Limited last traded at ₹81.65 with an intraday range of ₹78.2–₹82.5 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹81.65| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 91.97 | +10.32 | +12.64% |
| R3 | 87.67 | +6.02 | +7.37% |
| R2 | 85.08 | +3.43 | +4.20% |
| R1 | 83.37 | +1.72 | +2.10% |
| PIVOT | 80.78 | -0.87 | -1.06% |
| CURRENT | 81.65 | — | — |
| S1 | 70.47 | -11.18 | -13.70% |
| S2 | 74.77 | -6.88 | -8.43% |
| S3 | 76.48 | -5.17 | -6.33% |
| S4 | 79.07 | -2.58 | -3.16% |
VALIANTLAB is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Above opening range, showing Bullishness
Valiant Laboratories Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Valiant Laboratories Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Valiant Laboratories Limited stood at 75.2% of traded volume, against a 20-day average of 64.5%.
Valiant Laboratories announcements: results, concalls, ratings, M&A.
Filings Valiant Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Valiant Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 61 documents below.
Reply to Clarification- Financial results
The Exchange had sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI…
Action(s) taken or orders passed
Valiant Laboratories Limited has informed the Exchange about Action(s) taken or orders passed by the GST Authority
Disclosure under SEBI Takeover Regulations
Santosh Vora has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Disclosure under SEBI Takeover Regulations
Santosh Vora has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Clarification - Financial Results
The Exchange has sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI…
Investor decks & rating reports.
Valiant Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Valiant Laboratories has declared, sequenced by announce and record date.
Valiant Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Valiant Laboratories Limited: business, sector, key facts.
What Valiant Laboratories Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Valiant Laboratories Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: VALIANTLAB, BSE: 543998.
Valiant Laboratories Limited is an active pharmaceutical ingredient (API) and bulk drug manufacturing company with a global reach, headquartered in Mumbai, India. Their primary focus is on the production and distribution of paracetamol, a widely used analgesic and antipyretic drug. They manufacture paracetamol to meet the standards of various pharmacopoeias, including those of India, Britain, Europe, and the United States, ensuring compliance with diverse regulatory requirements across different markets.
The company's paracetamol production caters to a broad range of therapeutic applications. It is used to treat a variety of conditions including headaches, muscle aches, arthritis, backaches, toothaches, cold symptoms, and fever. This broad applicability contributes to a large potential market for their product.
Beyond paracetamol, Valiant Laboratories also offers a portfolio of specialty chemicals, though the specifics of these offerings are not detailed in the provided information. This diversification suggests a commitment to offering a wider range of products and services within the chemical and pharmaceutical industries.
Established in 1980 as Bharat Chemicals, the company rebranded as Valiant Laboratories Limited in August 2021. This rebranding may reflect a strategic shift in focus or an effort to enhance brand image and market positioning. Currently, Valiant Laboratories Limited operates as a subsidiary of Dhanvallabh Ventures LLP, indicating a larger corporate structure and potential access to greater resources and support.
In summary, Valiant Laboratories Limited is a well-established pharmaceutical company specializing in the manufacture and distribution of high-quality paracetamol and other specialty chemicals, supplying to a global market and meeting the stringent standards of multiple international pharmacopoeias. Their long history and recent rebranding demonstrate a commitment to sustained growth and innovation within the pharmaceutical industry.
Questions investors ask about Valiant Laboratories Limited (VALIANTLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Valiant Laboratories Limited (VALIANTLAB)?
The current share price of Valiant Laboratories Limited (VALIANTLAB) is ₹81.65. Today, the stock has gained by ₹2.03 (2.55%), trading in a range of ₹78.2 to ₹82.5. The stock opened at ₹80.8 with a trading volume of 87,489 shares.
02Is Valiant Laboratories Limited stock a good investment for long-term?
Valiant Laboratories Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹371.5 crores, P/E ratio of -111.23, ROE of -1.05%, and ROCE of -0.95%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Valiant Laboratories Limited stock?
The 52-week high price of Valiant Laboratories Limited (VALIANTLAB) is ₹123.88, while the 52-week low is ₹49.51. Currently trading at ₹81.65, the stock is 43.2% away from its 52-week low and 34.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Valiant Laboratories Limited stock at the current price?
Whether to buy Valiant Laboratories Limited stock at ₹81.65 depends on multiple factors. The stock is currently trading with a P/E ratio of -111.23 and P/B ratio of 1.17. Today's performance shows a gain of 2.55%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Valiant Laboratories Limited and when is the next dividend?
Valiant Laboratories Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹81.65, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Valiant Laboratories Limited?
Valiant Laboratories Limited's key financial metrics include: P/E Ratio: -111.23, P/B Ratio: 1.17, ROE: -1.05%, ROCE: -0.95%, Dividend Yield: 0.00%, EPS: ₹-0.05, Book Value: ₹50.08, and Debt-to-Equity: 0.00. The company's market cap stands at ₹371.5 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Valiant Laboratories Limited stock performing today in the market?
Valiant Laboratories Limited stock opened at ₹80.8 and is currently trading at ₹81.65, showing a gain of ₹2.03 (2.55%). The intraday high is ₹82.5 and low is ₹78.2. The trading volume stands at 87,489 shares, indicating moderate market participation today.
08What is the P/E ratio of Valiant Laboratories Limited and what does it indicate?
Valiant Laboratories Limited has a Price-to-Earnings (P/E) ratio of -111.23, which means investors are willing to pay ₹-111.23 for every ₹1 of earnings. With an EPS of ₹-0.05, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Valiant Laboratories Limited (VALIANTLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy